Sarepta Therapeutics' (SRPT) stock is climbing after Vertex Pharmaceuticals (VRTX) included in-depth information about Sarepta's treatment for Duchenne Muscular Dystrophy, or DMD, in a slide ...
- Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the NASDAQ OMX Investor Conference in London on Tuesday, ...
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex (VRTX) to submit first module before end of year - - Second pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback